The Cost-Effectiveness Analysis of Anaprazole Versus Ilaprazole for Treating Duodenal Ulcers in China

OBJECTIVES: To evaluate the economic efficacy of Anaprazole compared to Ilaprazole enteric coated tablets(Ilaprazole) in the treatment of duodenal ulcers (DU).

METHODS: From the perspective of the health system, this study utilized two multicenter randomized controlled trial (RCT) as data sources. we will compare the efficacy and safety of Anaprazole and Ilaprazole using anchored matching-adjusted indirect comparison (MAIC).

RESULTS: Cost-utility analysis (CUA) was conducted to assess the economic value of the two drugs based on a Markov model. To test the uncertainty in the model, deterministic sensitivity analysis (DSA) and probability sensitivity analysis (PSA) were performed Anaprazole and Ilaprazole are equally effective in treating duodenal ulcers (OR = 1.05, 95% CI, 0.94-1.01; P= 0.35). there was no significant difference in the incidence of adverse drug reactions (ADRs)between Ilaprazole and Anaprazole (OR = 0.6395% CI, 0.39-1.08; P= 0.12).The CUA results show that the ICUR value is 2995.41 ￥/QALY, which is lower than willingness to pay (WTP)DSA showed that the two most sensitive factors to the model were the drug cost of Anaprazole and Ilaprazole, respectively; PSA shows that when the WTP value is 85698.00 ￥，the probability of Anaprazole being more cost-effective than Ilaprazole is 85%.

CONCLUSIONS: Compared with Ilaprazole, Anaprazole have similar efficacy and safety when used for the treatment of DU. The ICUR value is lower than WTP, indicating good economic benefits and robust sensitivity analysis results.